PUMA BIOTECHNOLOGY INC (PBYI)
Health Care · Oncology biotech - HER2-targeted breast cancer therapeutics · NASDAQ
Biopharmaceutical company commercializing NERLYNX (neratinib), an irreversible HER2 tyrosine kinase inhibitor for HER2-positive breast cancer, and developing alisertib for multiple cancer indications.
What PUMA BIOTECHNOLOGY INC does
Puma Biotechnology is a biopharmaceutical company that develops and commercializes innovative products for cancer care. The company commercially markets NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for extended adjuvant treatment of early-stage HER2-positive breast cancer and for combination use in advanced/metastatic HER2-positive breast cancer. The company has in-licensed alisertib, an Aurora Kinase A inhibitor, and is pursuing global development and commercialization across multiple cancer indications including small cell lung cancer and hormone receptor-positive breast cancer.
Themes: ["HER2-positive breast cancer","Early-stage breast cancer (adjuvant treatment)","Metastatic breast cancer","Aurora Kinase A inhibition","Small cell lung cancer","Hormone receptor-positive breast cancer"]
Fundamentals
- Price$7.90 as of 2026-07-09 close
- Market cap$400M as of 2026-07-10
- 1-year return+119.4% as of 2026-07-09 close
- P/E16.42 as of 2026-07-10
- Net margin+10.7% as of 2026-07-10
- Gross margin+74.5% as of 2026-07-10
- ROE+20.4% as of 2026-07-10
- Debt / equity0.09 as of 2026-07-10
- Revenue growth (YoY)-2.4% as of 2026-07-10
- Revenue CAGR (3y)+0.0% SEC XBRL
- Beta1.24 as of 2026-07-10
Key risks (from latest filing)
["Revenue declining year-over-year (-2.38% YoY) despite profitability, indicating competitive pressure or market saturation in core breast cancer indications","Significant R&D spending increase (Q1 2026: $19.8M vs Q1 2025: $13.9M) to support alisertib development across multiple cancer types, creating cash burn risk","Dependency on NERLYNX commercialization and alisertib development success; competition from established HER2-targeting therapies (trastuzumab, pertuzumab, T-DM1, fam-trastuzumab deruxtecan, tucatinib)"]
Competitors & peers
- Roche/Genentech (trastuzumab, pertuzumab, T-DM1)
- Eli Lilly (tucatinib)
- Pfizer/Wyeth (lapatinib)
- Daiichi Sankyo (fam-trastuzumab deruxtecan)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.